Overview

Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML

Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
In this study we plan to improve the outcome of hematopoietic stem cell transplantation by using optimal busulfan dose through pharmacokinetic study.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Busulfan
Fludarabine
Fludarabine phosphate